Vertex PharmaceuticalsVRTX
About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Employees: 6,100
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
18% more first-time investments, than exits
New positions opened: 172 | Existing positions closed: 146
11% more call options, than puts
Call options by funds: $778M | Put options by funds: $699M
8% less repeat investments, than reductions
Existing positions increased: 532 | Existing positions reduced: 581
1.18% less ownership
Funds ownership: 92.36% [Q3] → 91.18% (-1.18%) [Q4]
4% less funds holding
Funds holding: 1,522 [Q3] → 1,468 (-54) [Q4]
14% less capital invested
Capital invested by funds: $111B [Q3] → $95B (-$15.6B) [Q4]
48% less funds holding in top 10
Funds holding in top 10: 29 [Q3] → 15 (-14) [Q4]
Research analyst outlook
15 Wall Street Analysts provided 1 year price targets over the past 3 months
15 analyst ratings
RBC Capital Brian Abrahams 16% 1-year accuracy 13 / 79 met price target | 16%downside $408 | Sector Perform Maintained | 20 Feb 2025 |
Canaccord Genuity Whitney Ijem 22% 1-year accuracy 9 / 41 met price target | 12%downside $424 | Hold Upgraded | 12 Feb 2025 |
Truist Securities Joon Lee 58% 1-year accuracy 26 / 45 met price target | 7%upside $520 | Buy Maintained | 11 Feb 2025 |
Scotiabank Greg Harrison 39% 1-year accuracy 13 / 33 met price target | 7%downside $450 | Sector Perform Maintained | 11 Feb 2025 |
Cantor Fitzgerald Olivia Brayer 39% 1-year accuracy 9 / 23 met price target | 1%downside $480 | Overweight Reiterated | 11 Feb 2025 |
Financial journalist opinion
Based on 83 articles about VRTX published over the past 30 days
